Photo by impulsq from unsplash
Key Points Question What is the current rate of adoption of first-line systemic treatment with fluorouracil, folinic acid, oxaliplatin, and irinotecan plus bevacizumab (FOLFOXIRI-B) in daily practice? Findings In this… Click to show full abstract
Key Points Question What is the current rate of adoption of first-line systemic treatment with fluorouracil, folinic acid, oxaliplatin, and irinotecan plus bevacizumab (FOLFOXIRI-B) in daily practice? Findings In this cross-sectional study of 282 patients in the Netherlands, FOLFOXIRI-B prescription rates marginally increased in the past 5 years. During the study period, 1 in 7 estimated, eligible patients was treated with FOLFOXIRI-B. Meaning The results of this study suggest that, despite evidence of the effectiveness of FOLFOXIRI-B therapy, use of this therapy for metastatic colorectal cancer remains low, possibly because of oncologists’ reported preference for doublet therapy.
Journal Title: JAMA Network Open
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!